J. Neurol. 2020 Feb 01
A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
Katsari M, Kasselimis DS, Giogkaraki E, Breza M, Evangelopoulos ME, Anagnostouli M, Andreadou E, Kilidireas C, Hotary A, Zalonis I, Koutsis G, Potagas C
Numerous cross-sectional studies report cognitive impairment in multiple sclerosis (MS), but longitudinal studies with sufficiently long-term follow-u ...
Read More
Source: PubMed
J. Neuroimmunol.
Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
Heming M, Lohmann L, Schulte-Mecklenbeck A, Brix T, Gross CC, Wiendl H, Klotz L, Meyer Zu Hörste G
Distinguishing neurosarcoidosis (NS) from multiple sclerosis (MS) remains challenging and available parameters lack discriminatory power. Comprehensiv ...
Read More
Source: PubMed
Int. Immunopharmacol.
Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis.
Karampoor S, Zahednasab H, Amini R, Esghaei M, Sholeh M, Keyvani H
It has been shown that the blockade of chemokine receptor type 5 can dampen inflammatory reaction within the central nervous system (CNS). In the pres ...
Read More
Source: PubMed
Mult Scler Relat Disord
A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-ß1a in multiple sclerosis patients.
Mallucci G, Patti F, Brescia Morra V, Buccafusca M, Moiola L, Amato MP, Ferraro E, Trojano M, Zaffaroni M, Mirabella M, Moscato G, Plewnia K, Zipoli V, Puma E, Bergamaschi R
Disease modifying therapy have changed the natural evolution of multiple sclerosis (MS), with efficacy demonstrated in randomized clinical trials. Sta ...
Read More
Source: PubMed
Mult Scler Relat Disord
In MS: Immunosuppression is passé.
Brod SA
Prolonged and significant alterations of the immune system by immunosuppression makes multiple sclerosis (MS) patients susceptible to opportunistic in ...
Read More
Source: PubMed
